Financing ·
Atrium Therapeutics prices $50M private placement of common stock and pre-funded warrants
RNAAtrium Therapeutics, Inc.
Atrium Therapeutics entered into a securities purchase agreement to sell 5,170,384 shares of common stock at $7.93 per share and pre-funded warrants for up to 1,134,930 additional shares at $7.929 each. The private placement is expected to generate approximately $50 million in gross proceeds before fees. Closing is anticipated on or about October 9, 2026. Proceeds will fund the development of lead product candidates and general corporate purposes, extending the company's cash runway through 2028. Atrium Therapeutics operates as a biopharmaceutical company advancing precision cardiology by developing RNA therapeutics targeted to the heart.